Descriptive Analysis of VTE Treatment With Rivaroxaban in Japanese Clinical Practice Using a Claims Database
Latest Information Update: 16 Jan 2023
Price :
$35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Sponsors Bayer
- 10 Jan 2023 Status changed from active, no longer recruiting to completed.
- 04 Nov 2022 Planned End Date changed from 30 Nov 2022 to 31 Dec 2022.
- 04 Nov 2022 Planned primary completion date changed from 30 Nov 2022 to 31 Dec 2022.